First Interstate Bank cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 103,332 shares of the biopharmaceutical company’s stock after selling 3,040 shares during the period. Gilead Sciences comprises approximately 1.6% of First Interstate Bank’s holdings, making the stock its 18th largest position. First Interstate Bank’s holdings in Gilead Sciences were worth $6,463,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in GILD. Vanguard Group Inc. boosted its holdings in shares of Gilead Sciences by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 97,167,329 shares of the biopharmaceutical company’s stock valued at $7,502,290,000 after purchasing an additional 1,071,619 shares during the last quarter. Vanguard Group Inc boosted its holdings in shares of Gilead Sciences by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 97,167,329 shares of the biopharmaceutical company’s stock valued at $7,502,290,000 after purchasing an additional 1,071,619 shares during the last quarter. Capital Research Global Investors boosted its holdings in shares of Gilead Sciences by 22.5% during the 3rd quarter. Capital Research Global Investors now owns 69,854,968 shares of the biopharmaceutical company’s stock valued at $5,393,502,000 after purchasing an additional 12,818,301 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Gilead Sciences by 199,789.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock valued at $2,420,587,000 after purchasing an additional 31,335,030 shares during the last quarter. Finally, Dodge & Cox boosted its holdings in shares of Gilead Sciences by 1.2% during the 3rd quarter. Dodge & Cox now owns 16,450,181 shares of the biopharmaceutical company’s stock valued at $1,270,118,000 after purchasing an additional 190,370 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Shares of NASDAQ GILD opened at $67.47 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.37 and a current ratio of 3.36. The stock has a market cap of $87.03 billion, a PE ratio of 10.97, a price-to-earnings-growth ratio of 66.46 and a beta of 1.19. Gilead Sciences, Inc. has a 12-month low of $60.32 and a 12-month high of $82.71.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.70 by ($0.26). Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same period last year, the company earned $1.78 earnings per share. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 6.23 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Investors of record on Friday, March 15th will be given a $0.63 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 dividend on an annualized basis and a yield of 3.73%. The ex-dividend date is Thursday, March 14th. Gilead Sciences’s dividend payout ratio is 37.07%.

In related news, Director John C. Martin sold 50,000 shares of the stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $71.20, for a total value of $3,560,000.00. Following the sale, the director now directly owns 2,877,762 shares of the company’s stock, valued at approximately $204,896,654.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.16% of the company’s stock.

GILD has been the subject of several research reports. Oppenheimer raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 price objective for the company in a report on Thursday, January 3rd. Citigroup reissued a “buy” rating and set a $100.00 price objective on shares of Gilead Sciences in a report on Tuesday. Zacks Investment Research downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Monday, December 31st. CIBC raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 price objective for the company in a report on Thursday, January 3rd. Finally, Wells Fargo & Co dropped their price objective on shares of Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating for the company in a report on Tuesday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $86.85.

TRADEMARK VIOLATION WARNING: “First Interstate Bank Decreases Holdings in Gilead Sciences, Inc. (GILD)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2019/02/09/first-interstate-bank-decreases-holdings-in-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Recommended Story: Yield Curve

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.